Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain |
| |
| Institution: | 1. Inovio Pharmaceuticals, Inc., 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422, USA;2. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA;3. Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Manitoba R2E 3R2, Canada;1. Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia;2. Centre “Bioengineering”, Russian Academy of Science, Moscow, Russia;1. AVIR Green Hills Biotechnology AG, Vienna, Austria;2. University of Natural Resources and Life Sciences, Vienna, Austria;1. Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, GA, USA;2. Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA;3. Georgia Institute of Technology, School of Chemical & Biomolecular Engineering, Atlanta, GA, USA;1. Vaxart Inc, South San Francisco, CA, USA;1. Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK;2. ENT Department, Alder Hey Children''s Hospital, Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK;3. ENT Department, Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK;4. Viral Pseudotype Unit, School of Pharmacy, University of Kent, Kent, UK;5. Department of Women''s and Children''s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK;6. The Jenner Institute, University of Oxford, ORCRB, Oxford, UK |
| |
| Abstract: | We previously reported a 2011/12 study in elderly showing that immunization with the universal influenza vaccine candidate, M-001, three weeks before administering trivalent influenza vaccine (TIV) enhanced seroconversion of Hemagglutination Inhibition (HAI) antibodies against known influenza vaccine strains circulating at that time. We now report that those subjects primed with M-001 prior to TIV in 2011 also showed, in their 2011 sera, significantly more HAI antibodies with improved seroprotection and seroconversion against strain A/Switzerland/9715293/2013(H3N2-like) that caused the 2014/15 influenza epidemic and that wasn’t known to circulate in 2011/12. These data indicate that M-001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years. The fact that M-001 stimulates T cell activation and is devoid of HA hypervariable epitopes indicates that such broadened HAI responses effected by M-001 priming is due to extensive T cell priming. |
| |
| Keywords: | Influenza Vaccine Universal CMI HAI Multimeric-001 M-001 Clinical trial |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
